Celgene reiterated by JMP at market outperform

Celgene Corp. was reiterated by JMP Securities analyst Charles C. Duncan at a market outperform rating and the price target was raised to $83 from $70. Celgene released its higher-than-expected pricing structure for Revlimid for myelodysplatic syndrome. Shares of the Summit, N.J., pharmaceutical company were up $0.4299, or 0.62%, at $69.97 on volume of 2,965,884 shares versus the three-month running average of 2368,770 shares. (Nasdaq: CELG)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.